found in the hemolymph of mated wild-type females where it is degraded into smaller non-functional peptides [19] . Taken together with the almost ubiquitous distribution of the SPR (see above) to many peripheral neurons and specific parts of the VNC and the brain [13] , these findings suggest that SP may have additional effects. The dsx + /fru + /ppk + neurons are very likely the primary targets. But SP entered into the hemolymph may in addition act by modulating the activity of the SP circuitry by modifying sensory input via binding to afferent nerve axons and/or directly on presynaptic terminals [7, [14] [15] [16] . Finally, stimulation of juvenile hormone synthesis and inducing the immune response in various organs very likely occurs via SP entered into the hemolymph [7] .
In sum, Rezaval et al. [3] have identified ascending neurons that target the brain, local interneurons and descending neurons that innervate the reproductive system. All express dsx and are involved in the SP response, hence confirming that fru and dsx are involved in establishing sexual dimorphic features of neural circuitry in fruit flies [1] . This is a major step towards understanding the complex function of a fascinating small male peptide. It will be interesting to learn how fru and dsx shape the development of the relevant neuronal circuitries. The relationship between cancer and inflammation has been a hot subject in research and medicine for centuries. The original observations by Galenius (2000 b.C), Virchow [1] and Dvorak [2] all suggested a close link between inflammation and cancer. As leukocytes are the first line of defense in immune responses, their presence in tumors has been hypothesized to have anti-cancer activity. In recent years, it has become clear, however, that the majority of tumor-associated leukocytes are there to promote tumor growth, tumor angiogenesis, invasion and metastasis. Two years ago, in a paper published in PLoS Biology, Feng et al. [3] reported that oncogene-transformed cells are able to attract leukocytes immediately after transformation, demonstrating an early trophic support provided by leukocytes to growing tumors. In a new study reported in this issue of Current Biology, Feng et al. [4] , using the same cancer model, now identify the signal that leukocytes provide to cancer cells to promote their survival.
To address these questions, Feng et al. [4] used genetic tools and chemical inhibitors to image cancer and inflammation in transparent zebrafish larvae. These authors employed a novel model of oncogene-induced transformation that targets a population of very superficial cells (the mucous-producing cells of the skin). These single cells, closely related to sebaceous gland mucous cells in mammals and sparse in the epidermis of zebrafish larvae, respond to oncogene expression by rapid, uncontrolled proliferation [5] . In their previous study, Feng et al. [3] had documented that the ability of transformed cells to attract leukocytes through a H 2 O 2 signal was beneficial to tumor cells, given that, in the absence of leukocytes, transformed cells did not proliferate and instead underwent apoptosis. The big question that remained unsolved in this earlier study was the nature of the trophic signal released by leukocytes that permitted growth of the transformed cells. In the new work, the search for the trophic signal ended with an interesting candidate, the eicosanoid prostaglandin E 2 (PGE 2 ), which has been involved in inflammation and cancer (reviewed in [6] ) and has a long history of helping cancer cells to survive, proliferate and invade [7] . Besides confirming the 'usual suspect' in a novel model of cancer-induced inflammation, the strongest points of the study lie in the use of combined genetic approaches and small chemical inhibitors to confirm the involvement of PGE 2 and its receptor E-prostanoid 1 (EP1) in the trophic support to transformed cells.
The authors use chemical inhibitors and morpholinos to knock down the enzymatic activities producing PGE 2 and pinpoint the specific pathway -namely microsomal rather than cytoplasmic PGEs -used by leukocytes to produce PGE 2 in the vicinity of Ras-transformed cells ( Figure 1A) . To overcome the problem of early lethality due to morpholino-mediated ablation of microsomal PGEs, they 'rescued' PGE 2 signaling during the first 9 hours of development by incubating embryos with the long-acting derivative of PGE 2 , 16,16-dimethyl-PGE 2 (dmPGE 2 ). This trick allowed them to study the effects of removing PGE 2 when oncogene-transformed cells most needed it, i.e. from the very beginning of transformation. Elegant lineage ablation studies and live observations in neutrophil-and macrophage-specific transgenic lines shed light on which of the two leukocyte cell populations contribute trophic PGE 2 to cancer cells. The answer is that PGE 2 is the only trophic signal produced by macrophages, whereas neutrophils contribute additional as yet unknown trophic products. Because of these detailed characterizations of the enzymatic pathway and of the innate immune cell populations involved, the study is likely to provide significant hints for advancing the search for specific drugs targeting the inflammation-cancer link.
Several questions are raised by this study and remain unresolved, with the exciting possibility of using the same or similar models to find the answers. First of all, how is PGE 2 , signaling through the EP1 receptor, sustaining cancer growth? There are studies reporting a role of PGE 2 in promoting Akt phosphorylation in neuroblastoma cells through calcium waves and cyclic AMP (cAMP) production [8] through different PGE 2 receptors. The four EP receptors (EP1-4) have multiple localizations (being found in the cell membrane, cytoplasm or nucleus), each related to specific downstream pathways in PGE 2 signaling ( Figure 1B ). Although these receptors are not mutually exclusive, their combinatorial expression or activation may lead to different outcomes. The possibility of using an in vivo model equipped with a wealth of genetic and chemical biology tools to tease apart the roles of different EP receptors in cancer is extremely exciting.
A recent report attributed to PGE 2 the repression of the DNA demethylases Dnmt1 and Dnmt3b and the corresponding increase in methylation of tumor suppressors in Apc Min/+ mice [9] as a mechanism to promote cancer. These mice are well known to PGE 2 aficionados as it was previously shown that lifetime administration of aspirin to these mice suppressed their intestinal and mammary tumors [10] . However, the mechanisms of Dnmt1/Dnmt3b repression by PGE 2 have not been clarified.
The Apc Min/+ mice provide a model for familial polyposis, a fairly common disease associated with APC mutations and cancer predisposition. Here the multiple adenomas forming in the colon of affected patients are sustained by increased Wnt signaling. Non-steroid anti-inflammatory drugs (NSAIDs) are commonly used for the treatment of familial polyposis, and reduction of PGE 2 levels with cyclo-oxygenase (COX) inhibitors has proven effective in suppressing increased Wnt signaling [11] .
One of the most tantalizing reports on the cancer-promoting function of PGE 2 is that of the activation of a Ras-MAPK-P-ERK cascade in APC Min mice bearing intestinal adenomas [12] . This is due to a self-amplifying loop that mimics activated Ras and relies on the induction of COX-2 in adenoma cells. It is possible that PGE 2 , locally produced by leukocytes, may have the same effect as the externally provided PGE 2 on tumor cells. Clearly, dissecting the different mechanisms through which PGE 2 ensures support to cancer cells may open up new avenues for intervention.
Another question is related to the expression of the PGE 2 receptors. It would be useful to know whether EP1 and other receptors are induced by the oncogene, as a means to provide transformed cells with the ability to respond to leukocyte PGE 2 . The implications of Ras-induced EP1 receptor expression are multiple. Besides representing an early marker of transformation, its selective blockage may have amplified responses in cancer prevention as this may be the key point in the PGE 2 -Ras activation loop. This loop is mostly mediated by a cAMP response induced by EP2/EP4 activation ( Figure 1B) , whereas early transformed cells in this model seem to express nuclear EP1. How do PGE 2 nuclear receptors regulate transcription or other nuclear events? One possibility is the convergence of EP1-mediated signals on Wnt target genes, which are induced by nuclear b-catenin accumulation. Indeed, the same EP2/EP4-mediated PKA and cAMP accumulation, which sustains the PGE 2 -Ras loop, is responsible for further stabilization of b-catenin [11] downstream of PGE 2 signaling ( Figure 1B ).
Can we prevent cancer by targeting the pathways downstream of PGE 2 ? While the overlapping molecular pathways described earlier provide experimental support for this possibility, the 'proof of principle' that targeting innate inflammatory responses in cancer will have anti-tumor effects comes from clinical evidence. Treating chronic inflammation in patients often led to regression of associated cancer, and long-term supply of regular aspirin or other NSAID therapies for the prevention of cardiovascular disorders strongly decreased the incidence of cancer in a large cohort study [13] . In a mouse model of acute myeloid leukemia, the reversible COX inhibitor indomethacin was shown to strongly reduce leukemia-initiating cells through repression of Wnt-b-catenin signaling [14] . NSAIDs function by inhibiting COX-1 and COX-2, which are responsible for the production of all prostaglandins from fatty acids ( Figure 1A ), but the processes that are affected by a reduction of prostaglandin levels are too numerous to be specific for the cancer-inflammation axis. For example, prostaglandins regulate hormonal activities, coagulation, angiogenesis, vasodilation [15] and hematopoietic stem cell homing and transplantation [16] , just to mention a few.
The wide range of actions of NSAIDs explains the decision not to pursue a clinical trial in cancer patients, in spite of the impressive clinical data gathered by Rothwell et al. [13] , which revealed a reduction by 30-60% of the 20-year risk of cancer death. Most importantly, the reasons for the premature drop in the use of NSAIDs in cancer prevention came from the dramatic outcome of gastrointestinal bleeding and increased thrombocytic events that accompanied the long-term usage of NSAIDs and specific COX-2 inhibitor derivatives in cardiovascular disease prevention trials [17] . Studies like the report by Feng et al. [4] will contribute a great deal to develop cancer-specific anti-PGE 2 therapies.
Ultimately, this latest report from Feng et al. [4] provides a novel perspective on inflammation and cancer: usually this complex relationship has been tackled from the point of view of infectious agents as cancer inducers (viruses or bacteria through inflammation) or cancer co-factors (inflammation). Here, cancer-initiating cells (expressing an oncogene) are inflammatory (most likely in advanced cancer [18] ), even before any morphological or behavioral difference from their untransformed siblings becomes apparent. The new study also provides the hope that altering prostaglandin levels can help prevent cancer.
